within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A04A_AntiemeticsAndAntinauseants.A04AD10_Dronabinol;

model Dronabinol
  extends Pharmacolibrary.Drugs.ATC.A.A04AD10;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A04AD10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (THC), the principal psychoactive constituent of cannabis. It is used primarily as an antiemetic in the treatment of chemotherapy-induced nausea and vomiting and as an appetite stimulant in AIDS-related anorexia. Dronabinol is approved for these uses in several countries including the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers (both sexes), single oral administration.</p><h4>References</h4><ol><li><p>Hansen, JS, et al., &amp; Svendsen, KB (2024). Pharmacokinetics and pharmacodynamics of cannabis-based medicine in a patient population included in a randomized, placebo-controlled, clinical trial. <i>Clinical and translational science</i> 17(1) e13685–None. DOI:<a href=\"https://doi.org/10.1111/cts.13685\">10.1111/cts.13685</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38054364/\">https://pubmed.ncbi.nlm.nih.gov/38054364</a></p></li><li><p>Heuberger, JA, et al., &amp; Freijer, J (2015). Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics. <i>Clinical pharmacokinetics</i> 54(2) 209–219. DOI:<a href=\"https://doi.org/10.1007/s40262-014-0195-5\">10.1007/s40262-014-0195-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25316574/\">https://pubmed.ncbi.nlm.nih.gov/25316574</a></p></li><li><p>Ahmed, AI, et al., &amp; Kramers, C (2014). Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial. <i>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</i> 24(9) 1475–1482. DOI:<a href=\"https://doi.org/10.1016/j.euroneuro.2014.06.007\">10.1016/j.euroneuro.2014.06.007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25035121/\">https://pubmed.ncbi.nlm.nih.gov/25035121</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Dronabinol;
